HomeCompareCFXA vs KMB

CFXA vs KMB: Dividend Comparison 2026

CFXA yields 9.75% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMB wins by $24.5K in total portfolio value
10 years
CFXA
CFXA
● Live price
9.75%
Share price
$177.71
Annual div
$17.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full CFXA calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — CFXA vs KMB

📍 KMB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCFXAKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CFXA + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CFXA pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFXA
Annual income on $10K today (after 15% tax)
$828.36/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, KMB beats the other by $4,428.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFXA + KMB for your $10,000?

CFXA: 50%KMB: 50%
100% KMB50/50100% CFXA
Portfolio after 10yr
$33.6K
Annual income
$2,606.18/yr
Blended yield
7.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CFXA right now

CFXA
Analyst Ratings
12
Buy
9
Hold
2
Sell
Consensus: Buy
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFXA buys
0
KMB buys
6
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$KMB▼ Sell$1,001 - $15,0002025-11-12
Ro Khanna🏢 House$KMB▼ Sell$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$KMB▼ Sell$1,001 - $15,0002025-09-05
Lisa McClain🏢 House$KMB▼ Sell$1,001 - $15,0002025-07-16
Lisa McClain🏢 House$KMB▲ Buy$1,001 - $15,0002025-07-10
Rob Bresnahan🏢 House$KMB▼ Sell$1,001 - $15,0002025-05-15
Rob Bresnahan🏢 House$KMB▼ Sell$1,001 - $15,0002025-04-08
Julie Johnson🏢 House$KMB▼ Sell$1,001 - $15,0002025-04-01
Ro Khanna🏢 House$KMB▲ Buy$1,001 - $15,0002024-11-15
Tommy Tuberville🏛 Senate$KMB▼ Sell$15,001 - $50,0002024-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCFXAKMB
Forward yield9.75%5.25%
Annual dividend / share$17.32$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%17%
Portfolio after 10y$21.4K$45.9K
Annual income after 10y$1.04$5,211.33
Total dividends collected$1.0K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: CFXA vs KMB ($10,000, DRIP)

YearCFXA PortfolioCFXA Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$11,187$487.27$11,314$613.68$127.00KMB
2$12,225$254.73$12,865$759.19$640.00KMB
3$13,211$130.07$14,709$943.96$1.5KKMB
4$14,201$65.68$16,919$1,180.17$2.7KKMB
5$15,228$32.99$19,588$1,484.33$4.4KKMB
6$16,311$16.53$22,838$1,879.06$6.5KKMB
7$17,461$8.27$26,832$2,395.60$9.4KKMB
8$18,687$4.14$31,788$3,077.63$13.1KKMB
9$19,998$2.07$38,000$3,986.82$18.0KKMB
10$21,399$1.04$45,872$5,211.33$24.5KKMB

CFXA vs KMB: Complete Analysis 2026

CFXAStock

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine/life sciences, pipelines, mobile/off-highway equipment, oil, gas, and mining markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and direct and independent distributors under the DJO brand. Colfax Corporation was founded in 1860 and is based in Wilmington, Delaware.

Full CFXA Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this CFXA vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFXA vs SCHDCFXA vs JEPICFXA vs OCFXA vs KOCFXA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.